Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 4/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9051591 | 1.00 | SLC6A2 (0.49) | SLC6A2SLC6A4SLC6A3ALDH1A1GAA | |
| SCHEMBL9051592 | 0.91 | SLC6A2 (0.47) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL14076272 | 0.87 | SLC6A2 (0.44) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL21958656 | 0.87 | SLC6A2 (0.44) | SLC6A2SLC6A4SLC6A3ALDH1A1GAA | |
| SCHEMBL17052871 | 0.87 | SLC6A2 (0.44) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL14188732 | 0.87 | SLC6A2 (0.44) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL14820116 | 0.87 | SLC6A2 (0.44) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL1709025 | 0.82 | SLC6A2 (0.41) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL9965973 | 0.80 | — | — | |
| SCHEMBL23269576 | 0.78 | SLC6A2 (0.55) | SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9181277-B2 | Aminoquinazoline derivatives and their salts and methods of use | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2015-11-10 | — | — | US | disclosed |
| US-20140228361-A1 | AMINOQUINAZOLINE DERIVATIVES AND THEIR SALTS AND METHODS OF USE | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2014-08-14 | — | — | US | disclosed |
| WO-1996007656-A1 | CIS-HEXAHYDRO-5-(2-NAPHTHALENYL)PYRROLO<3,4-c>PYRROLES | ELI LILLY AND COMPANY (US) | 1996-03-14 | — | — | WO | disclosed |
| US-5457121-A | Cis-hexahydro-5-(1,2,3,4-tetrahydro-2-naphthalenyl)pyrrolo<3,4-c>pyrroles as inhibitors of serotonin reuptake | ELI LILLY AND COMPANY (US) | 1995-10-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140228361-A1 | AMINOQUINAZOLINE DERIVATIVES AND THEIR SALTS AND METHODS OF USE | ABL1, PRKDC, JAK2 | SLC6A2 2205/4885SLC6A4 2361/4885SLC6A3 2481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.